What is the role of anti-VEGF therapy in the treatment of choroidal neovascularization (CNV) treated?

Updated: Jul 27, 2020
  • Author: Lihteh Wu, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Anti-VEGF treatment counters angiogenesis and increased vascular permeability; accumulation of subretinal fluid secondary to increased permeability is an important component of decreased vision in CNV. [2]

The major limitation of anti-VEGF treatment is the injection burden. Most patients require multiple injections. Therefore, a number of different protocols are looking at combining photodynamic therapy, corticosteroids, and anti-VEGF drugs. [3, 4, 5, 6, 7]

Currently, the treatment of choice for CNV secondary to exudative age-related macular degeneration (ARMD) is intravitreal anti-VEGF therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!